The estimated Net Worth of Chrystal Jensen is at least 1.77 百万$ dollars as of 15 August 2024. Chrystal Jensen owns over 16,667 units of Cerus stock worth over 972,202$ and over the last 12 years Chrystal sold CERS stock worth over 796,051$.
Chrystal has made over 14 trades of the Cerus stock since 2016, according to the Form 4 filled with the SEC. Most recently Chrystal sold 16,667 units of CERS stock worth 34,501$ on 15 August 2024.
The largest trade Chrystal's ever made was exercising 211,327 units of Cerus stock on 22 December 2020 worth over 923,499$. On average, Chrystal trades about 23,854 units every 106 days since 2013. As of 15 August 2024 Chrystal still owns at least 474,245 units of Cerus stock.
You can see the complete history of Chrystal Jensen stock trades at the bottom of the page.
Chrystal's mailing address filed with the SEC is C/O CERUS CORPORATION, 1220 CONCORD AVE SUITE 600, CONCORD, CA, 94520.
Over the last 21 years, insiders at Cerus have traded over 5,083,598$ worth of Cerus stock and bought 1,382,745 units worth 4,903,526$ . The most active insiders traders include William Mariner Greenman、Laurence M Corash、Bruce C Cozadd. On average, Cerus executives and independent directors trade stock every 33 days with the average trade being worth of 90,805$. The most recent stock trade was executed by Kevin Dennis Green on 3 September 2024, trading 82,657 units of CERS stock currently worth 178,539$.
cerus corporation is a biomedical products company focused on commercializing the intercept blood system to enhance blood safety. the intercept system is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. the nucleic acid targeting mechanism of action enables intercept treatment to inactivate established transfusion threats, such as hepatitis b and c, hiv, west nile virus and bacteria, and is designed to inactivate emerging pathogens such as influenza, malaria and dengue. cerus currently markets and sells the intercept blood system for both platelets and plasma in europe, russia, the middle east and selected countries in other regions around the world. the intercept red blood cell system is in clinical development.
Cerus executives and other stock owners filed with the SEC include: